Research programme: enoyl-acyl carrier protein reductase inhibitors - Aurigene

Drug Profile

Research programme: enoyl-acyl carrier protein reductase inhibitors - Aurigene

Alternative Names: Fabl inhibitors - Aurigene

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aurigene Discovery Technologies
  • Class Small molecules
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in India
  • 02 Apr 2013 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top